Industry Strength Score
34/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
INNATE PHARMA SA (IPH.PA) Stock Price & Overview
EPA:IPH • FR0010331421
Current stock price
1.2 EUR
+0.01 (+0.5%)
Last:
The current stock price of IPH.PA is 1.2 EUR. Today IPH.PA is up by 0.5%. In the past month the price increased by 13.45%. In the past year, price decreased by -39.13%.
IPH.PA Key Statistics
52-Week Range1.03 - 2.1
Current IPH.PA stock price positioned within its 52-week range.
1-Month Range1.07 - 1.464
Current IPH.PA stock price positioned within its 1-month range.
- Market Cap
- 112.596M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.55
- Dividend Yield
- N/A
IPH.PA Stock Performance
Today
+0.5%
1 Week
+3.81%
1 Month
+13.45%
3 Months
-22.61%
Longer-term
6 Months -28.35%
1 Year -39.13%
2 Years -45.67%
3 Years -53.92%
5 Years -66.35%
10 Years -90.52%
IPH.PA Stock Chart
IPH.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IPH.PA. When comparing the yearly performance of all stocks, IPH.PA is a bad performer in the overall market: 95.16% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
IPH.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IPH.PA. IPH.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IPH.PA Earnings
On April 1, 2026 IPH.PA reported an EPS of -0.55 and a revenue of 2.79M. The company missed EPS expectations (-353.8% surprise) and beat revenue expectations (25.56% surprise).
Next Earnings DateN/A
Last Earnings DateApr 1, 2026
PeriodQ1 / 2026
EPS Reported-€0.55
Revenue Reported2.79M
EPS Surprise -353.80%
Revenue Surprise 25.56%
IPH.PA Forecast & Estimates
8 analysts have analysed IPH.PA and the average price target is 6.27 EUR. This implies a price increase of 422.75% is expected in the next year compared to the current price of 1.2.
For the next year, analysts expect an EPS growth of 13.33% and a revenue growth -2.22% for IPH.PA
Analysts
Analysts82.5
Price Target6.27 (422.5%)
EPS Next Y13.33%
Revenue Next Year-2.22%
IPH.PA Financial Highlights
Over the last trailing twelve months IPH.PA reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 10.35% compared to the year before.
Income Statements
Revenue(TTM)2.79M
Net Income(TTM)-49.18M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.41% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%0.82%
Sales Q2Q%-74.22%
EPS 1Y (TTM)10.35%
Revenue 1Y (TTM)-77.92%
IPH.PA Ownership
Ownership
Inst Owners8.34%
Shares93.83M
Float69.67M
Ins Owners1.22%
Short Float %N/A
Short RatioN/A
IPH.PA Industry Overview
IPH.PA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
21%
Outperformed 21% of sub-industries
3 Month Rank
19%
Outperformed 19% of sub-industries
6 Month Rank
34%
Outperformed 34% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.2
- Average Fwd P/E
- 30.2
- Average Debt/Equity
- 0.0
IPH.PA Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.82 | 40.797B | ||
| 1AE | ARGENX SE | 28.8 | 40.784B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.748B | ||
| ABVX | ABIVAX SA | N/A | 7.414B | ||
| 2X1 | ABIVAX SA | N/A | 7.402B | ||
| GXE | GALAPAGOS NV | N/A | 1.583B | ||
| GLPG | GALAPAGOS NV | N/A | 1.58B | ||
| NANO | NANOBIOTIX | N/A | 1.367B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1B | ||
| PHARM | PHARMING GROUP NV | 47.31 | 997.578M | ||
| PHGN | PHARMING GROUP NV | 47.15 | 992.281M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 873.421M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About IPH.PA
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
IPO: 2006-10-31
INNATE PHARMA SA
117 avenue de Luminy, Bp 30191
Marseille PACA FR
Employees: 163
Phone: 33430303030
INNATE PHARMA SA / IPH.PA FAQ
Can you describe the business of INNATE PHARMA SA?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
What is the current price of IPH stock?
The current stock price of IPH.PA is 1.2 EUR. The price increased by 0.5% in the last trading session.
Does IPH stock pay dividends?
IPH.PA does not pay a dividend.
How is the ChartMill rating for INNATE PHARMA SA?
IPH.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is INNATE PHARMA SA (IPH.PA) stock traded?
IPH.PA stock is listed on the Euronext Paris exchange.
What is the market capitalization of IPH stock?
INNATE PHARMA SA (IPH.PA) has a market capitalization of 112.60M EUR. This makes IPH.PA a Micro Cap stock.